Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia – comparison of real-world data from 2004-2005 and 2017-2018

Piret Lõiveke (✉ Piret.Loiveke@regionaalhaigla.ee)  
University of Tartu, Department of Cardiology

Toomas Marandi  
North Estonia Medical Centre, Quality Department

Tiia Ainla  
North Estonia Medical Centre, Centre of Cardiology

Krista Fischer  
University of Tartu, Institute of Mathematics and Statistics

Jaan Eha  
Tartu University Hospital

Research Article

Keywords: Myocardial infarction, secondary prevention, medication adherence, guideline adherence

DOI: https://doi.org/10.21203/rs.3.rs-290073/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Relatively high rates of adherence to myocardial infarction (MI) secondary prevention medications have been reported, but register-based, objective real-world data is scarce.

We aimed to analyse adherence to guideline-recommended medications for secondary prevention of MI in 2017-2018 (period II) and compare the results with data from 2004-2005 (period I) in Estonia.

**Methods:** Study populations were formed based on data from the Estonian Health Insurance Fund's database and on Estonian Myocardial Infarction Register. By linking to the Estonian Medical Prescription Centre database adherence to guideline-recommended medications for MI secondary prevention was assessed for one year follow-up period from the first hospitalization due to MI. Data was analysed using the defined daily dosages methodology.

**Results:** Total of 6694 and 6060 cases of MI were reported in periods I and II, respectively. At least one prescription during the follow up period was found for beta-blockers (BB) in 81.0 % and 83.5 % (p = 0.001), for angiotensin converting enzyme inhibitor/angiotensin II receptor blocker (ACEi/ARB) in 76.9 % and 66.0 % (p < 0.001), and for statins in 44.0 % and 67.0 % (p < 0.001) of patients in period I and II, respectively. P2Y12 inhibitors were used by 76.4 % of patients in period II. The logistic regression analysis adjusted to gender and age revealed that some drugs and drug combinations were not allocated similarly in different age and gender groups.

**Conclusions:** In Estonia, adherence to MI secondary prevention guideline-recommended medications has improved. But as adherence is still not ideal more attention should be drawn to MI secondary prevention through systematic guideline implementation.

**Background**

In recent years, a significant slowdown has occurred in the declining pace of CV mortality in high-income countries. It can, at least partly, be attributed to the rapidly growing populations of diabetic, obese and octogenarian people. It has been shown that nearly half of the considerable decline in CV mortality in the past decades can be explained by the use of evidence based medical treatment and interventions and approximately 44 % by the reductions in major risk factors (1). The potential of the guideline-recommended therapies has not been fully realized. So now, the key to further lowering CV mortality, may lie in better adherence to secondary prevention medical treatment and risk factor control (2).

In Estonia, during the last decades, CV mortality has declined and reached a level of 198/100 000 in 2017 (3). Highest CV mortality rate in the Western Europe was 158/100 000 observed in the 1970s (4, 5). Assuming, Estonia is following the CV mortality course of the western European countries with a time shift, a stagnation of the favourable trend is imminent.
Moderate to high rates of adherence to MI secondary prevention guideline-recommended medications have been reported in Europe by several different studies (6, 7) e.g. the EUROASPIRE V (8).

As could be expected, results vary according to the study method used. Some studies of MI secondary prevention guideline-recommended medication adherence analyse data of selected patient populations, often drawing the age limit at 75 or 80 years (3) or excluding patients for other reasons (medication not initiated at discharge, absence of certain insurance coverage, complications of treatment or disease, concomitant conditions) (6, 9). Oftentimes, medication adherence is evaluated based on patient interviews (3) or targeting to only some recommended drug classes (4). Therefore, registry based objective real-world data of secondary prevention medication adherence is scarce.

Western population as a whole is ageing. Therefore, the mean age of MI patients is increasing, also in Estonia. The demographic group of elderly patients is becoming more prominent with problems of multiple comorbidities and frail overall condition. It poses new challenges to physicians and the whole society. So far, the majority of MI secondary prevention medication adherence studies have focused on population groups of < 80 years of age, so information from registry-based studies of unselected patient populations is of great value in evaluating the medication adherence in the real world.

In Estonia, collecting data of all MI patients in a comprehensive registry started in 2012. Ongoing data collection of an unselected patient population with linking data to the Estonian Causes of Death Registry and the Estonian Medical Prescription Center (EMPC) database on the individual level is a unique opportunity to evaluate treatment and outcome changes on a complete population cohort over time.

The aim of our study was to analyse adherence to guideline-recommended medications for secondary prevention of MI in 2017–2018 and compare the results with data from 2004–2005 in Estonia.

Methods

Estonian Myocardial Infarction Register (EMIR) is a national ongoing register collecting data regarding all patients hospitalized with diagnosis of acute MI (International Classification of Diseases 10th version (ICD-10) codes I21-I22) from all Estonian hospitals. EMIR was founded in 2012 and approximately 2700 cases are reported annually. Data reporting is mandatory by law. An electronic form comprising nearly 100 characteristics about patients' CV risk factors, concomitant diseases, in-hospital treatment (procedures and medications) and recommended drug therapy at discharge is used. EMIR is linked annually with the Estonian Causes of Death Registry and Estonian Health Insurance Fund (EHIF) database by personal identification number.

EHIF is a national health insurance schema based on solidarity and equality meaning that working social taxpayers ensure equal quality and availability of health care services to all people covered by the insurance (working people, children and adolescences, elderly, pregnant women). In 2018 94.5% of the Estonian population was covered with the health insurance (5). A database of all hospitalizations of
insured patients is available. Data about prescribed and reimbursed medications is collected in the EMPC.

For adequate comparison of the results, this study was designed similarly to the one carried out in 2010 by Marandi et al. using the defined daily dosages methodology (6). Briefly, for the earlier study the EHIF prepared a list of inpatients treated for MI (ICD-10 code I21-I22) during the period of 01.01.2004–31.12.2005 (period I). This list was then used to identify all prescriptions of statins (Anatomical Therapeutic Chemical Classification System (ATC) code C10AA), ACEis (ATC code C09AA), ARBs (ATC code C09CA) and BBs (ATC code C07A) reimbursed to these MI patients during a 12-month period (365 days) after the index episode. In the final analysis, data of patients who survived > 30 days from the index episode was used. Mortality data was obtained from the Estonian Population Registry for the 12-month period after the index episode. The index episode was defined as the first hospitalization due to MI during study period.

For the present study a list of patients was acquired from EMIR comprising all cases of MI (ICD-10 codes I21-I22) from 01.01.2017–31.12.2018 (period II). This list was linked to the EHIF’s database and the Estonian Causes of Death Registry. An index episode was defined as the first hospitalization of a person due to MI during the study period. Follow up time was defined as 365 days period after the index episode. Information regarding patients who lived > 30 days after the index episode was used in analysis of drug utilization. A list of medications of interest prescribed and reimbursed during the period of 183 days prior (i.e., patient had a valid prescription for medication of interest at the index episode time) and 365 days after the index episode was issued by the EMPC. Medications of interest were guideline recommended drugs for secondary prevention of MI (7) - statins, Aces, ARBs, BBs, clopidogrel (ATC code B01AC04) and ticagrelor (ATC code B01AC24). All medications reimbursed were considered as used by the patient.

To analyse drug use for secondary prevention the daily defined dosages (DDD) methodology was used. It is a methodology developed by World Health Organisation (WHO): a defined daily dosage is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDDs were as follows: atorvastatin 20 mg, simvastatin 30 mg, fluvastatin 60 mg, rosuvastatin 10 mg, pravastatin 30 mg, ramipril 2.5 mg, enalapril 10 mg, perindopril 4 mg, fosinopril 15 mg, lisinopril 10 mg, trandolapril 2 mg, telmisartan 40 mg, losartan 50 mg, valsartan 80 mg, candesartan 8 mg, olmesartan 20 mg, carvedilol 37.5 mg, metoprolol 150 mg, propranolol 160 mg, sotalol 160 mg, atenolol 75 mg, nebivolol 5 mg, bisoprolol 10 mg, clopidogrel 75 mg, ticagrelor 180 mg (8). As antiaggregants, only P2Y12 inhibitors clopidogrel and ticagrelor were studied. Acetylsalicylic acid is an over-the-counter drug and no reliable information for its utilization is available. Prasugrel is not reimbursed by the EHIF and was very rarely used some years ago in Estonia. DDDs were summarized based on drug class and divided by patient’s lifedays during follow-up.

All methods were carried out in accordance with relevant guidelines and regulations. It is permitted by law to use personal data from EMIR without informed consent of the participants for research purposes and linking with other national databases (e.g. EHIF, EMPC, Estonian Cause of Death
Personal data from registries was pseudonymized and handled according to all personal data protection requirements with the approval of the Research Ethics Committee of the University of Tartu.

**Statistical analysis**

Categorical data were expressed as frequencies and compared with Pearson's \( \chi^2 \) test. Age was presented as mean with standard deviation and compared between genders with the two-sample t-test. The DDDs were summarized based on drug class and expressed as medians per life days by age groups. 95% confidence intervals for medians and α values for comparison between genders were obtained with Mann Whitney U test. Logistic regression models were fitted to explore associations between age, sex and allocated drugs and drug combinations. Results were expressed as odds ratios with 95% confidence intervals. Comparison of results between studies regarding periods I and II was done using frequency tables.

An \( \alpha \) value of < 0.01 was considered significant. Analysis was performed with statistical software package RStudio version 1.2.5033 (RStudio, Boston, Massachusetts, USA).

**Results**

Total of 6694 and 6060 cases of MI were reported and out of these 4900 and 5067 index episodes were defined in periods I and II, respectively. Mean age for men was 65.66 years (SD ± 11.56) and 67.5 years (SD ± 12.3) and for women 73.61 years (SD ± 9.81) and 77.4 years (SD ± 10.9) in period I and II, respectively. In comparison of period I vs II the 30-day and 1-year mortality decreased (Table 1). Also, the mean age for both gender groups rose over the past 13 years.

| Characteristics of study populations. | Period I (2004–2005) | Period II (2017–2018) | P value (comparison between periods) |
|--------------------------------------|----------------------|-----------------------|-------------------------------------|
| Total number of index episodes, (%)  | 2772 (56.6)          | 2128 (43.4)*          |                                     |
| One-year mortality, No. (%)          | 709 (25.6)           | 744 (35.0)*           |                                     |
| 30-day mortality, No. (%)            | 407 (15.0)           | 468 (22.0)*           |                                     |
**Study population**

|                                | 2365 (85.3) | 1660 (78.0)* | 2704 (89.0) | 1668 (82.2)* | < 0.001 |
|--------------------------------|-------------|--------------|-------------|--------------|---------|
| Number of patients who survived > 30 days, (%) |             |              |             |              |         |
| Age (years; mean, ± SD)        | 64.7 ± 11.5 | 72.7 ± 9.9*  | 66.5 ± 12.1 | 76.4 ± 10.9* | < 0.001 |
| 20–39 years, No. (%)           | 34 (1.4)    | 4 (0.2)      | 29 (1.1)    | 6 (0.4)      |         |
| 40–59 years, No. (%)           | 740 (31.3)  | 166 (10.0)   | 779 (28.8)  | 126 (7.6)    |         |
| 60–79 years, No. (%)           | 1383 (58.5) | 1075 (64.8)  | 1498 (55.4) | 835 (50.0)   |         |
| > 80 years, No. (%)            | 208 (8.8)   | 415 (25.0)   | 398 (14.7)  | 701 (42.0)   |         |
| One-year mortality, No. (%)    | 302 (12.8)  | 276 (16.6)*  | 246 (9.1)   | 242 (14.5)*  | < 0.001 |

*p < 0.01 for comparison between genders. Age was compared with the t-test, otherwise Pearson's χ² test was used.

**Drug utilization**

In period I 94.4 % of patients who survived > 30 days were treated with at least one drug of the recommended classes (statins, BBs, ACEis/ARBs). In period II, out of the 4372 patients who survived > 30 days, 4009 (91.7 %) were treated with at least one of the guideline recommended drugs for MI secondary prevention (statins, ACEis/ARBs, BBs or P2Y12 inhibitors).

In Fig. 1 median daily dosages of BBs, ACEis/ARBs and statins are presented as DDDs per lifeday with 95% confidence interval for age groups and gender in comparison of two study periods.

Median daily dosages for P2Y12 inhibitors were calculated only for period II and were consistently around 1.00 for all age and gender groups with the exception of the > 80 years age group. For this age group median daily dosages for P2Y12 inhibitors were 0.84 (95 % CI 0.69–0.92) for men and 0.61 (95 % CI interval 0.46–0.77) for women with a p = 0.0009.

With the exception of ACEi/ARB, representatives of all guideline-recommended drug classes were prescribed significantly more often in period II than in period I for patients who survived > 30 days after MI (Table 2).
Table 2
Proportion of patients with at least one prescription for guideline-recommended medications among patients who survived >30 days.

|                           | Period I 2004–2005 (n = 4025) | Period II 2017–2018 (n = 4372) |                  |                  |      |                  |                  |                  |                  |
|---------------------------|-------------------------------|--------------------------------|------------------|------------------|------|------------------|------------------|------------------|------------------|
|                           | Men                           | Women                         | Total            | Men              | Women | Total            | P value (comparison between periods) |
| BB, No. (%)               | 1907 (80.6)                   | 1344 (81.0)                   | 3251 (81.0)      | 2265 (84.0)      | 1385 (83.0) | 3650 (83.5)      | 0.001             |
| Ace/ARB, No. (%)          | 1780 (75.3)                   | 1317 (79.3)                   | 3097 (76.9)      | 1817 (67.2)      | 1070 (64.1) | 2887 (66.0)      | < 0.001           |
| Statins, No. (%)          | 946 (40.0)                    | 826* (50.0)                   | 1772 (44.0)      | 1910 (70.6)      | 1020* (61.2) | 2930 (67.0)      | < 0.001           |
| P2Y12 inhibitors, No. (%) | NA                            | NA                            | NA               | 2194 (81.1)      | 1147* (69.0) | 3341 (76.4)      | NA                |

BB, beta-blockers; Ace/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers. NA, not available. Pearson's χ² test used for comparison between periods. *P < 0.01 for comparison between men and women with Pearson's χ² test.

Combinations of prescribed treatments for patients who survived >30 days for the two study periods are presented in Table 3.
Table 3
Combinations of prescribed treatments for patients who survived > 30 days.

|                          | Period I                              | Period II                              | P value         |
|--------------------------|---------------------------------------|----------------------------------------|-----------------|
|                          | 2004–2005 (n = 4025)                 | 2017–2018 (n = 4372)                  | (comparison between periods) |
|                          | Men                                   | Women                                  | Men             | Women             |
| Only BB, No. (%)†        | 176 (7.4)                             | 123 (7.4)                              | 158 (5.8)       | 141* (8.5)        | 0.314            |
| Only Ace/ARB, No. (%)†   | 170 (7.2)                             | 145 (8.3)                              | 39 (1.4)        | 31 (1.9)          | < 0.001          |
| Only Statin, No. (%)†    | 17 (0.7)                              | 12 (0.7)                               | 37 (1.3)        | 25 (1.5)          | 0.003            |
| BB + Ace/ARB, No. (%)†   | 602 (25.5)                            | 525* (31.6)                            | 338 (12.5)      | 301* (18.0)       | < 0.001          |
| BB + statins, No. (%)†   | 130 (5.5)                             | 49* (3.0)                              | 433 (16.0)      | 257 (15.4)        | < 0.001          |
| Ace/ARB + statin, No. (%)† | 141 (6.0)                           | 63* (3.8)                              | 104 (3.8)       | 52 (3.1)          | 0.001            |
| BB + ACEi/ARB + statin, No. (%)† | 999 (42.2)                         | 647 (39.0)                             | 1336 (49.4)     | 686* (41.1)       | < 0.001          |
| None of the above medications, No. (%) | 130 (5.5)                              | 96 (6.0)                               | 214 (7.9)       | 148 (9.0)         | < 0.001          |

BB, beta-blockers; Ace/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers.
NA, not available. P2Y12 inhibitor use not accounted for. Pearson's $\chi^2$ test used for comparison between periods. *P < 0.01 for comparison between men and women with Pearson's $\chi^2$ test.

Frequency of prescribing the triple combination of BBs, ACEis/ARBs and statins had increased (in total 40.8 % in period I vs 46.2 % in period II, p < 0.01) and a difference between genders had appeared.

In Fig. 2 results of logistic regression analysis for associations of drug allocation and gender for periods I and II are presented. Prescriptions for P2Y12 inhibitors were analysed only for period II. It was found that women were prescribed P2Y12 inhibitors significantly less often (OR 0.61, 95% CI 0.51–0.73, p < 0.001).

BB, beta-blockers; ACEi/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers; OR, odds ratio. Men were used as reference groups for logistic regression model.

Results of logistic regression for drug allocation and age groups in both study periods are presented in Table 4.
Table 4
Relationship of drug allocation and age in patients who survived >30 days in 2004–2005 (period I) and 2017–2018 (period II).

| Drug allocation | 20–59 years; OR (95% CI) | 60–79 years; OR (95% CI) | > 80 years; OR (95% CI) |
|-----------------|--------------------------|--------------------------|-------------------------|
|                 | 2004–2005 2017–2018      | 2004–2005 2017–2018      |                         |
| BB              | 1.00                     | 0.97 (0.29–3.19)         | 1.00 (0.73–1.39)        |
|                 | 1.00                     | 1.00 (0.73–1.39)         | 1.93 (0.58–6.47)        |
|                 | 1.08                     | (0.75–1.58)              |                         |
| Ace/ARB         | 1.00                     | 2.49* (1.67–3.70)        | 1.38 (0.67–3.12)        |
|                 | 1.00                     | 5.69* (3.66–8.82)        | 3.16**                  |
|                 | 1.00                     | (1.49–7.35)              |                         |
| Statins         | 1.00                     | 0.88 (0.38–2.06)         | 1.32 (0.68–2.75)        |
|                 | 1.00                     | 0.17 (0.02–1.37)         | 1.45 (0.50–2.69)        |
|                 | 1.00                     | (0.50–2.69)              |                         |
| Ace/ARB + BB    | 1.00                     | 1.21 (0.57–2.57)         | 1.06 (0.84–1.36)        |
|                 | 1.00                     | 1.92 (0.89–4.14)         | 1.85**                  |
|                 | 1.00                     | (1.42–2.42)              |                         |
| Ace/ARB + statin| 1.00                     | 0.32* (0.12–0.84)        | 1.06 (0.7–1.72)         |
|                 | 1.00                     | 0.19* (0.06–0.58)        | 1.09 (0.66–1.81)        |
|                 | 1.00                     | (0.66–1.81)              |                         |
| Statin + BB     | 1.00                     | 0.81 (0.24–2.66)         | 1.01 (0.82–1.25)        |
|                 | 1.00                     | 0.28 (0.08–1.06)         | 0.75*                   |
|                 | 1.00                     | (0.57–0.97)              |                         |
| BB + Ace/ARB + statin | 1.00 | 1.02 (0.53–1.96) | 0.93 (0.79–1.09) |
|                 | 1.00                     | 0.28* (0.14–0.55)        | 0.72**                  |
|                 | 1.00                     | (0.59–0.87)              |                         |
| None of the above | 1.00                   | NA                       | 1.31 (1.00–1.73)        |
|                 | 1.00                     | NA                       | 1.66**                  |
|                 | 1.00                     | (1.20–1.30)              |                         |
| BB + Ace/ARB + statin + P2Y12 inhibitor | 1.00 | NA | 0.82* (0.70–0.94) |
|                 | 1.00                     | NA                       | 0.52**                  |
|                 | 1.00                     | (0.42–0.63)              |                         |
| P2Y12 inhibitor | 1.00                     | NA                       | 1.31 (1.00–1.73)        |
|                 | 1.00                     | NA                       | 1.66**                  |
|                 | 1.00                     | (1.20–1.30)              |                         |
BB, beta-blockers; Ace/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers; OR, odds ratio; CI, confidence interval. Due to small number of patients in 20–39 years and 40–59 years age groups they were merged and used as reference groups for logistic regression model. *p < 0.05; **p < 0.001 for comparison between age groups within one time period.

It can be seen that still the triple combination of BBs, ACEis/ARBs and statins was prescribed less often to older patients. Also, a significant difference between age groups was observed for P2Y12 inhibitors in period II (60–79 years OR 0.48, 95 % CI 0.35–0.65, p < 0.001; > 80 years OR 0.18, 95 % CI 0.13–0.24, p < 0.001).

**Discussion**

Our study found that guideline-recommended medications for MI secondary prevention were prescribed more often in period II than in period I but there are significant differences among age and gender subgroups. BBs are still prescribed in smaller dosages than recommended in guidelines. In addition, we found that during the past 13 years the mean age of MI patients has increased but the 30-day and 1-year mortality of MI patients in Estonia decreased significantly.

A positive shift has taken place in prescribing guideline recommended MI secondary prevention medications in Estonia, but our patients’ rate of adherence is still lower than in several studies conducted elsewhere in Europe. The EUROASPIRE V study (3) looking into secondary prevention practices in 27 European countries reported 81 % of patients receiving BBs, 75 % receiving ACEis or ARBs and 80% receiving statins after > 6 months from MI. 93 % of patients received anti-platelets in EUROASPIRE V, but aspirin, besides P2Y12 inhibitors, was also counted for. It is of importance, that only patients < 80 years of age were included in EUROASPIRE V and data was derived from patient interviews. Gross et al. (9) also reported high adherence to MI secondary prevention medications in an intervention program with regular visits to office-based cardiologist in Germany, proving that in a selected group of highly motivated patients who are willing to participate in high intensity secondary prevention programs, good results are achievable. But in every day practice, as did also our data show, on unselected patient populations the results are far from ideal with moderate rates of adherence also reported by Huber et al. in Switzerland (10).

In our study an unselected population of MI patients was observed, and it was evident that women and the elderly (patients in > 80 years age group) were considerably less likely to receive statins and P2Y12 inhibitors. Saar et al. (11) showed that in Estonia, elderly patients, who comprise nearly 80 % of the GRACE score high risk population, undergo percutaneous coronary intervention (PCI) and use P2Y12 inhibitors significantly less often during hospitalization. Also, a correlation between performing PCI and use of P2Y12 inhibitors in other age groups was demonstrated.
In addition, we found that the triple combination of BBs, ACEis/ARBs and statins was significantly less often prescribed to women and the elderly. Again, these findings correlate to other studies on unselected population (10) and could partly explain lower rates of adherence in our study compared to results from selected patient populations.

It is common practice that physicians are cautious when prescribing secondary prevention medications to elderly patients with the concerns of possible adverse effects, drug-drug interactions and questionable benefit in mind (15–17). Recently evidence has shown that elderly patients do benefit from guideline recommended secondary prevention drug therapy after MI without any substantial additional harm (18–21).

Also, the fact that women use less guideline recommended MI secondary prevention drug treatment is a recognized phenomenon though the reasons behind it are not well known (16, 22–23).

Rate of prescribing BBs has increased significantly over time in Estonia. However, regardless of sex and age, beta blocking agents were used in relatively small dosages – an issue also evident in 2004. It is a universally recognized problem which still is not very well explained (12). At one hand, the length of hospital stay is increasingly shortening and follow up visits are infrequent which discourage general practitioners from up titrating the initial dose. On the other hand, evidence form research has risen the question of appropriateness of the guideline recommended doses (13) and indication of BBs in the PCI, antiplatelet and statin era (14).

The number of patients to whom no secondary prevention medications were prescribed, had risen from 5.6 % in period I to 8.3 % in period II. The majority of these patients were in the > 60 years age groups, for 42.4 % of these patients no coronary angiography was performed. 18.5 % of them died during the follow up in the period II cohort. No description for the period I cohort was available. The reasons for this slight negative tendency can only be assumed (e.g., more patients survive out of hospital cardiac arrest who remain with a profound cognitive deficit and are managed in nursing homes, some patients leave the country etc.) and need to be investigated further.

In Estonia, the CV disease mortality rate is declining. The MI in hospital management has improved considerably (15) as can be concluded from the decreased 30-day mortality rate. But as the number of diabetics and overweight patients, often already in younger age groups, and octogenarians is increasing, solutions for achieving and maintaining MI secondary prevention guideline recommended goals (including high adherence to medical therapy), are needed (16).

Strengths and limitations

The major strength of this study is the characteristics of the data – full representation of the MI patients’ population without a selection bias. Also, information is available without interviewer bias or recall bias.

Our study has certain limitations. Firstly, the defined daily dosages methodology used is not the most accurate and probably overestimates adherence slightly. It was chosen, instead of medication possession
rate methodology, to enable comparison with the previously conducted study using the DDD methodology. By using this methodology, we cannot differentiate everyday-users from short-time-users of certain drug.

Secondly, there is no data available to confirm whether the patients actually take the purchased medications. So, the actual usage is probably lower than the presented results. But still, accounting reimbursed prescriptions as used medications by patient is a validated methodology (17).

Thirdly, we do not have any information to explain the reasons behind nonadherence nor for not finding any prescriptions in the database for some patients.

Fourthly, we have no data about contraindications or information about intolerance of recommended dosages regarding individual patients which may explain some of the nonadherence to guidelines.

**Conclusions**

In Estonia, adherence to MI secondary prevention guideline-recommended medications has improved over 13 years. According to our results, adherence is still not ideal, more attention should be drawn especially to women and the elderly. A systematic approach for delivering MI guideline-recommended secondary prevention should be implemented in Estonia, to reduce the CV mortality further.

**List Of Abbreviations**

ACEi angiotensin converting enzyme inhibitor

ARB angiotensin receptor antagonist

ATC Anatomical Therapeutic Chemical Classification System

BB beta blocker

CI confidence interval

CV cardiovascular

DDD daily defined dosages

EHIF Estonian Health Insurance Fund

EMIR Estonian Myocardial Infarction Register

EMPC Estonian Medical Prescription Center

EUROASPIRE European Action on Secondary and Primary Prevention by Intervention to Reduce Events
GRACE score The Global Registry of Acute Coronary Events score

ICD-10 International Classification of Diseases 10th version

MI myocardial infarction

OR odds ratio

PCI percutaneous coronary

SD standard deviation

WHO World Health Organisation

Declarations

Ethics approval

Study was approved by the Research Ethics Committee of the University of Tartu (298T-11).

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the Estonian Research Council. Grant number PRG435.

Authors’ contributions

PL, TM, TA and JE participated in interpreting the data and writing the manuscript. PL and KF analysed the data. All authors read and approved the final manuscript.

Acknowledgements

We thank the Estonian Health Insurance Fund and the Estonian Medical Prescription Centre for providing the datasets for statistical analysis and Gudrun Veldre from The Estonian Myocardial Infarction Register.
for the list of patients included in the analysis. Also, we thank Jaak Asser for helping out with constructing the figures.

References

1. Mensah GA, Wei GS, Sortie PD, Fine LJ, Rosenberg Y, Kaufmann PG, et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. *Circa Res.* 2017 Jan 20; 120 (2): 366-380. DOI: 10.1161/CIRCRESAHA.116.309115

2. Sachem U, Achenbach S, Andreotti F, Arden C, Buda A, Giardini R, et al. 2013 ESC guidelines on the management of stable coronary artery disease—addenda. *Eur Heart J* 2013 Oct 7; 34 (38): 2949-3003. DOI: 10.1093/eurheartj/eht296

3. Cardiovascular mortality in Estonia 2000-2019 [Internet]. Statistics Estonia. [cited 2020 December 18]. Available from: https://andmed.stat.ee/et/stat/rahvastik__rahvastikusundmused__surmad/RV56

4. Death due to other ischaemic heart diseases, by sex [Internet]. Eurostat. [cited 2020 December 18]. Available from: https://ec.europa.eu/eurostat/databrowser/view/tps00119/default/table?lang=en

5. Levi F, Zucchini F, Negri E, Vecchio CL. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. *Heart* 2002; 88: 119-124.

6. Goss F, Brachman J, Hamm CW, Hearer W, Rifat N, Levenson B. High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: 1-year outcomes of the Pronator Study. *Vass Health Risk Manga.* 2017 Apr 6; 2017 (13): 127-137. DOI: 10.2147/VHRM.S119490

7. Huber CA, Meyer MR, Stoffel J, Brozik E, Reich O, Roseman T. Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population. *Clin There.* 2019 Jan; 41 (1): 107–17. DOI: 10.2147/VHRM.S119490

8. Kostelac K, De Backer G, De Lacquer D, Rydin L, Hoes A, Grubbed D. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. *Eur J Prep Cardio.* 2019 May; 26 (8): 824–35. DOI: 10.1177/2047487318825350

9. Basial S, Castellano JM, Garrido E, Wei HG, Freeman A, SPTel C, et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. *J Am Coll Cardio.* 2016 Aug; 68 (8): 789–801. DOI: 10.1016/j.jacc.2016.06.005

10. Estonian Health Insurance Fund [Internet]. [cited 2020 November 28]. Available from: https://www.haigekassa.ee/haigekassa/majandusaruanded-ja-eelarve

11. Marandi T, Babur in A, Alina T. Use of evidence-based pharmacotherapy after myocardial infarction in Estonia. *BMC Public Health.* 2010 Dec; 10 (1): 358. DOI: 10.1186/1471-2458-10-358

12. Peploi MF, Hoes AW, Age wall S, Albus C, Bretons C, Catepan AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European
Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Eur Heart J. 2016 Aug 1; 37 (29): 2315–81. DOI: 10.1186/1471-2458-10-358

13. WHO Collaborating Centre for Drug Statistics Methodology [Internet]. [cited 2020 November 20]. Available from: https://www.whocc.no/atc_ddd_index/

14. Saar A, Marandi T, Alina T, Fischer K, Blondal M, Ehab J. The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk. Int J Cardio. 2018 Aug; 272: 26-32. DOI: 10.1016/j.ijacard.2018.08.015

15. Baja A, Bemol DG, Furan P, Bartonella C, Casals P, Baldovin T. Tackling inequalities: are secondary prevention therapies for reducing post-infarction mortality used without disparities? Eur J Prep Cardio. 2014 Feb; 21 (2): 222-30. DOI: 10.1177/2047487312462148

16. Pereira M, Araujo C, Dias P, Lunette N, Sabiana I, Maruga J. Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study. Eur J Prep Cardio. 2014; 2014 Nov (21): 1401–8. DOI: 10.1177/2047487313494580

17. Music S, Wang SS, Schwabe K, Slide L, Waters E, Yeh CS. Underutilization of statin therapy for secondary prevention of cardiovascular disease among older adults. Popup Health Manga. 2019 Feb; 22 (1): 74–82. DOI: 10.1089/pop.2018.0051

18. Dauji AA, Rami eddy A, Álvaro L, Forman DE. Secondary cardiovascular prevention in older adults: an evidence based review. J Geriatric Cardio. 2015; 12: 459–64. DOI: 10.11909/j.issn.1671-5411.2015.05.019

19. Zulu AR, Mogul A, Corsa K, Shah NR, Lee SJ, Rudolph JL, et al. Association between secondary prevention medication use and outcomes in frail older adults after acute myocardial infarction. Circa Cardiovasc Qual Outcomes. 2019 Apr; 12:e004942. DOI: 10.1161/CIRCOOUTCOMES.118.004942

20. Gender B, Marston NA, I'm K, Cannon CP, Sever P, Keech A et al. Meta-analysis of randomised controlled trials. The Lancet. 2020 Nov 21; 396 (10263): 1637–43. DOI: 10.1016/S0140-6736(20)32332-1

21. Rosa RD, Piscine F, Galasso G, Serve SD, Saponite S. Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes. J Geriatric Cardio. 2019; 16: 103-113. DOI: 10.11909/j.issn.1671-5411.2019.02.006

22. Redford B. Women are less likely to get secondary prevention medications and cardiac rehabilitation. [Internet]. 2017 Oct 31. [cited 2020 December 20]. Available from: https://www.acc.org/Latest-in-Cardiology/Articles/2017/10/30/15/02/Women-Are-Less-Likely-to-Get-Secondary-Prevention-Medications-and-CR

23. Zhao M, Woodward M, Varèse I, Millett ERC, Klipstein-Grobusch K, Hyun K, et al. Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis. J Am Heart Assoc. 2020 Jun 2; 9 (11). DOI: 10.1161/JAHA.119.014742
24. Goldberger JJ, Bono RO, Cuffe M, Dyer A, Rosenberg Y, O'Rourke R, et al. β-Blocker use following myocardial infarction: low prevalence of evidence-based dosing. *Am Heart J.* 2010 Sep; 160 (3): 435-442.e1. DOI: 10.1016/j.ahj.2010.06.023

25. Goldberger JJ, Bono RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. *J Am Coll Cardio.* 2015 Sep; 66 (13): 1431–41. DOI: 10.1016/j.jacc.2015.07.047

26. Arabic MD, Sandmen I, Dodo TB, Gale CP, Ruddock V, Munchausen J. Effect of oral b-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. *Eur Heart J - Cardiovasc Pharmacotherapy.* 2019; 5: 12–20. DOI: 10.1093/ehjcwp/pvy034

27. Saar A, Marandi T, Alina T, Fischer K, Ehab J . Improved treatment and prognosis after acute myocardial infarction in Estonia: cross-sectional study from a high risk country. *BMC Cardiovasc Discord.* 2015 Oct 26; 15; Article number 136. DOI: 10.1186/s12872-015-0129-7

28. Solomon MD, Leong TK, Levin E, Rana JS, Jaffe MG, Sidney S, et al. Cumulative adherence to secondary prevention guidelines and mortality after acute myocardial infarction. *J Am Heart Assoc.* 2020 Mar 17; 9 (6). DOI: 10.1161/JAHA.119.014415

29. Lam WY, Fresco P. Medication Adherence Measures: An Overview. *BioMed Res Int.* 2015; 2015: 1–12. DOI: 10.1155/2015/217047

**Figures**
Figure 1

Median daily dosages of statins, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) and betablockers (BB) presented as defined daily dosages (DDD) per lifeday with 95% confidence interval for age groups and gender for patients who survived > 30 days in comparison of periods I (2004-2005) and II (2017-2018).
Figure 2

Relationship of drug allocation and gender in patients who survived > 30 days. BB, beta-blockers; ACEi/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers; OR, odds ratio. Men were used as reference groups for logistic regression model.